187 related articles for article (PubMed ID: 31550048)
1. VEGF-Trap is a potent modulator of vasoregenerative responses and protects dopaminergic amacrine network integrity in degenerative ischemic neovascular retinopathy.
Rojo Arias JE; Economopoulou M; Juárez López DA; Kurzbach A; Au Yeung KH; Englmaier V; Merdausl M; Schaarschmidt M; Ader M; Morawietz H; Funk RHW; Jászai J
J Neurochem; 2020 May; 153(3):390-412. PubMed ID: 31550048
[TBL] [Abstract][Full Text] [Related]
2. Gene expression profile of the murine ischemic retina and its response to Aflibercept (VEGF-Trap).
Rojo Arias JE; Jászai J
Sci Rep; 2021 Jul; 11(1):15313. PubMed ID: 34321516
[TBL] [Abstract][Full Text] [Related]
3. Aflibercept (VEGF-TRAP): the next anti-VEGF drug.
Stewart MW
Inflamm Allergy Drug Targets; 2011 Dec; 10(6):497-508. PubMed ID: 21999177
[TBL] [Abstract][Full Text] [Related]
4. [Management of aflibercept in routine clinical practice].
Cabrera López F
Arch Soc Esp Oftalmol; 2015 Mar; 90 Suppl 1():29-34. PubMed ID: 25925049
[TBL] [Abstract][Full Text] [Related]
5. VEGF-Trap Modulates Retinal Inflammation in the Murine Oxygen-Induced Retinopathy (OIR) Model.
Rojo Arias JE; Englmaier VE; Jászai J
Biomedicines; 2022 Jan; 10(2):. PubMed ID: 35203414
[TBL] [Abstract][Full Text] [Related]
6. Capacity of aflibercept to counteract VEGF-stimulated abnormal behavior of retinal microvascular endothelial cells.
Deissler HL; Lang GK; Lang GE
Exp Eye Res; 2014 May; 122():20-31. PubMed ID: 24631334
[TBL] [Abstract][Full Text] [Related]
7. [Role of VEGF in diseases of the retina].
Barquet LA
Arch Soc Esp Oftalmol; 2015 Mar; 90 Suppl 1():3-5. PubMed ID: 25925044
[TBL] [Abstract][Full Text] [Related]
8. Anti-vascular endothelial growth factor treatment for retinal conditions: a systematic review and meta-analysis.
Pham B; Thomas SM; Lillie E; Lee T; Hamid J; Richter T; Janoudi G; Agarwal A; Sharpe JP; Scott A; Warren R; Brahmbhatt R; Macdonald E; Straus SE; Tricco AC
BMJ Open; 2019 May; 9(5):e022031. PubMed ID: 31142516
[TBL] [Abstract][Full Text] [Related]
9. Fusion Proteins: Aflibercept (VEGF Trap-Eye).
Sarwar S; Bakbak B; Sadiq MA; Sepah YJ; Shah SM; Ibrahim M; Do DV; Nguyen QD
Dev Ophthalmol; 2016; 55():282-94. PubMed ID: 26501481
[TBL] [Abstract][Full Text] [Related]
10. Effects of anti-VEGF treatment on the recovery of the developing retina following oxygen-induced retinopathy.
Tokunaga CC; Mitton KP; Dailey W; Massoll C; Roumayah K; Guzman E; Tarabishy N; Cheng M; Drenser KA
Invest Ophthalmol Vis Sci; 2014 Mar; 55(3):1884-92. PubMed ID: 24550366
[TBL] [Abstract][Full Text] [Related]
11. Aflibercept: an update on recent milestones achieved.
Palejwala NV; Lauer AK
Drugs Today (Barc); 2014 Dec; 50(12):779-90. PubMed ID: 25588083
[TBL] [Abstract][Full Text] [Related]
12. CNTF Attenuates Vasoproliferative Changes Through Upregulation of SOCS3 in a Mouse-Model of Oxygen-Induced Retinopathy.
Bucher F; Walz JM; Bühler A; Aguilar E; Lange C; Diaz-Aguilar S; Martin G; Schlunck G; Agostini H; Friedlander M; Stahl A
Invest Ophthalmol Vis Sci; 2016 Aug; 57(10):4017-26. PubMed ID: 27494343
[TBL] [Abstract][Full Text] [Related]
13. Antiangiogenic effect of betaine on pathologic retinal neovascularization via suppression of reactive oxygen species mediated vascular endothelial growth factor signaling.
Park SW; Jun HO; Kwon E; Yun JW; Kim JH; Park YJ; Kang BC; Kim JH
Vascul Pharmacol; 2017 Mar; 90():19-26. PubMed ID: 27473515
[TBL] [Abstract][Full Text] [Related]
14. Aflibercept, a VEGF (Vascular Endothelial Growth Factor)-Trap, Reduces Vascular Permeability and Stroke-Induced Brain Swelling in Obese Mice.
Kim ID; Cave JW; Cho S
Stroke; 2021 Aug; 52(8):2637-2648. PubMed ID: 34192895
[TBL] [Abstract][Full Text] [Related]
15. Complete RPE and outer retinal atrophy in patients receiving anti-VEGF treatment for neovascular age-related macular degeneration.
Eng VA; Rayess N; Nguyen HV; Leng T
PLoS One; 2020; 15(5):e0232353. PubMed ID: 32369500
[TBL] [Abstract][Full Text] [Related]
16. Endogenous erythropoietin protects neuroretinal function in ischemic retinopathy.
Mowat FM; Gonzalez F; Luhmann UF; Lange CA; Duran Y; Smith AJ; Maxwell PH; Ali RR; Bainbridge JW
Am J Pathol; 2012 Apr; 180(4):1726-39. PubMed ID: 22342523
[TBL] [Abstract][Full Text] [Related]
17. A novel model of persistent retinal neovascularization for the development of sustained anti-VEGF therapies.
Li Y; Busoy JM; Zaman BAA; Tan QSW; Tan GSW; Barathi VA; Cheung N; Wei JJ; Hunziker W; Hong W; Wong TY; Cheung CMG
Exp Eye Res; 2018 Sep; 174():98-106. PubMed ID: 29852133
[TBL] [Abstract][Full Text] [Related]
18. Aflibercept: newly approved for the treatment of macular edema following central retinal vein occlusion.
Evoy KE; Abel SR
Ann Pharmacother; 2013 Jun; 47(6):819-27. PubMed ID: 23673531
[TBL] [Abstract][Full Text] [Related]
19. [New drug VEGF Trap-Eye--Eylea--and its use in the treatment of age-related macular degeneration, central retinal vein occlusion, diabetic macular edema, and choroidal neovascularization secondary to pathologic myopia].
Rejdak R; Szkaradek M; Taslaq W; Kałuzny JJ; Grieb P; Jünemann AG
Klin Oczna; 2012; 114(4):308-10. PubMed ID: 23461161
[TBL] [Abstract][Full Text] [Related]
20. Trends of Anti-Vascular Endothelial Growth Factor Use in Ophthalmology Among Privately Insured and Medicare Advantage Patients.
Parikh R; Ross JS; Sangaralingham LR; Adelman RA; Shah ND; Barkmeier AJ
Ophthalmology; 2017 Mar; 124(3):352-358. PubMed ID: 27890437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
